Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Atacand Dose Range Finding Study in Pediatric Subjects 6 to <17 Years of Age

ClinicalTrials.gov ID: NCT00244634

Public ClinicalTrials.gov record NCT00244634. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 8, 2026, 12:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Dose-Ranging and Safety Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects 6 to <17 Years of Age: A 4-Week, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Study 261A is a dose-ranging and safety study of candesartan cilexetil. It is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel-group study with a 4 week treatment period in hypertensive pediatric subjects. Subjects undergo a screening evaluation, then a 1-week, single-blind, placebo run-in after which eligible subjects are allocated to receive 1 of 3 dose levels of candesartan cilexetil or placebo. The study includes 2 panels based on subject weight. The primary efficacy analysis is based on the intent-to-treat population and tests for slope = 0 in a linear regression model with change in sitting systolic blood pressure as the dependent and non-zero dose pooled across weight panels as the independent variable. For subjects without a Double-Blind Week 4 blood pressure determination, carrying the last value forward assigns the value. Additional analyses will include data pooled from a similar dose ranging study conducted in children 1 to \< 6 years of age.

Study identification

NCT ID
NCT00244634
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
238 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
6 Years to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2003
Primary completion
Not listed
Completion
Oct 31, 2005
Last update posted
Dec 18, 2007

2003 – 2005

United States locations

U.S. sites
36
U.S. states
21
U.S. cities
36
Facility City State ZIP Site status
Research Site Beverly Hills California
Research Site Los Angeles California
Research Site Madera California
Research Site Yuba City California
Research Site Newark Delaware
Research Site Wilmington Delaware
Research Site Miami Florida
Research Site Athens Georgia
Research Site Augusta Georgia
Research Site Chicago Illinois
Research Site Park Ridge Illinois
Research Site Louisville Kentucky
Research Site Ann Arbor Michigan
Research Site Jackson Mississippi
Research Site Port Gibson Mississippi
Research Site St Louis Missouri
Research Site Las Vegas Nevada
Research Site Paterson New Jersey
Research Site Brooklyn New York
Research Site New Hyde Park New York
Research Site The Bronx New York
Research Site Charlotte North Carolina
Research Site Winston-Salem North Carolina
Research Site Cincinnati Ohio
Research Site Cleveland Ohio
Research Site Columbus Ohio
Research Site Portland Oregon
Research Site Philadelphia Pennsylvania
Research Site Pittsburgh Pennsylvania
Research Site Charleston South Carolina
Research Site Beaumont Texas
Research Site Houston Texas
Research Site Salt Lake City Utah
Research Site Charlottesville Virginia
Research Site Norfolk Virginia
Research Site Charleston West Virginia

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00244634, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 18, 2007 · Synced Sep 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00244634 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →